NCT/Study#

APTEVO

Phase 1-2 study of a bispecific CD3xCD123 antibody in Acute Myeloid Leukemia patients

Phase 1-2 study of a bispecific CD3xCD123 antibody in Acute Myeloid Leukemia patients

DISEASE GROUP:
Leukemia
current phase:
Phase I/II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: